PubMed Health⌕ Search

PubMed · 16754115

Tumor implantation during laparoscopy using different insufflation gases - an experimental study using cultured cancer cells.

Abstract

Recent work using an experimental model in our laboratory has shown that the likelihood of tumor implantation at laparoscopy port-sites following laparoscopy might be influenced by the specific gas used for insufflation. In particular helium insufflation was associated with less port site metastases. The model entailed an inbred rat strain and a tumor cell suspension of mixed heterogeneity, native to the rat strain. To determine whether our previous findings could be reproduced using a different model, we investigated the effect of insufflation with either helium or carbon dioxide gas on the implantation of a purified cell suspension of cultured cancer cells. Thirty-eight Dark Agouti rats were randomized to undergo a 40 minute period of laparoscopic insufflation with either helium or carbon dioxide (19 animals in each group/three different experiments). Three laparoscopy ports were placed and 2 x 10 5 cultured mammary adenocarcinoma cells were introduced into the abdominal cavity at the beginning of the period of insufflation. The rats were killed nine days after surgery and the port sites and abdominal cavity were examined for presence of tumor. Rats undergoing helium insufflation were equally likely to develop port-site metastases compared to rats undergoing carbon dioxide insufflation. There was, however, a predilection for port site metastases to develop at the port site used for camera placement in both groups. Because this port site accommodated a 2 mm laparoscope, it was associated with a larger wound than the other two port sites. Peritoneal tumor deposits elsewhere in the peritoneal cavity were more common following helium insufflation, compared to carbon dioxide. The outcome of this study is different to the results from previous studies using a heterogeneous tumor cell suspension in the same model in our laboratory, or elsewhere, with no advantages demonstrated for insufflation with helium gas. Purified cell suspensions could behave differently to a heterogeneous cell suspension of identical cancer cells in a port-site implantation model, and other cells present within heterogeneous tumor suspension might influence the likelihood of metastasis. As reported previously, tumor implantation is more likely in larger port site wounds and this is independent of the insufflation gas.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ludemann, Watson, Smith, Ellis, Jamieson. 2003. Tumor implantation during laparoscopy using different insufflation gases - an experimental study using cultured cancer cells.. https://doi.org/10.1080/13645700310017868

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗